03rd week of 2010 patent applcation highlights part 48 |
Patent application number | Title | Published |
20100016186 | Thermally Stable Subsea Control Hydraulic Fluid Compositions - An aqueous hydraulic fluid composition comprising of one or more lubricants such as a monovalent metal salt, ammonium, or amine salt of a dicarboxylic acid, such as a C21 dicarboxylic acid is described in which the aqueous hydraulic fluid composition demonstrates increased thermal stability when exposed to elevated temperatures for a prolonged period of time while being able to tolerate the presence of 10% v/v synthetic seawater. The aqueous hydraulic fluid composition contains less than about 20% by weight (preferably none or substantially none) of an oil selected from the group consisting of mineral oils, synthetic hydrocarbon oils, and mixtures thereof. The hydraulic fluid hereof preferably comprises a cyclical or ring base tertiary amine with no hydroxyl functionality such as 1,4-dimethyl piperazine. | 2010-01-21 |
20100016187 | Environmental Subsea Control Hydraulic Fluid Compositions - An aqueous hydraulic fluid composition comprising (i) a salt of formic acid, and (ii) one or more lubricants such as a monovalent metal salt, ammonium, or amine salt of a dicarboxylic acid, is described in which the aqueous hydraulic fluid composition demonstrates increased thermal stability when exposed to elevated temperatures for a prolonged period of time while being able to tolerate the presence of 10% v/v synthetic seawater. The aqueous hydraulic fluid composition contains less than about 20% by weight (preferably none or substantially none) of an oil selected from the group consisting of mineral oils, synthetic hydrocarbon oils, and mixtures thereof. The hydraulic fluid preferably contains no glycols in some embodiments. The pH of the hydraulic fluid is preferably from 8 to 10 and is maintained by a buffer which preferably comprises borax in some embodiments. | 2010-01-21 |
20100016188 | Antiwear Agent and Lubricating Compositions Thereof - The present invention relates to an antiwear agent and lubricating compositions thereof. The invention further provides for a method of lubricating a driveline device or a grease application by employing a lubricating composition containing the antiwear agent. | 2010-01-21 |
20100016189 | Method of Lubricating and Lubricating Compositions Thereof - The present invention relates to a method of lubricating a mechanical device by using a lubricating composition containing a thiadiazole-functionalised dispersant. The invention further provides a lubricating composition suitable for the mechanical device containing a thiadiazole-functionalised dispersant and a polysulphide. | 2010-01-21 |
20100016190 | ELECTRICAL OIL COMPOSITION - An electrical oil composition comprising: A) dc-asphalted cylinder oil (DACO) having a benzo [a] pyrene content of not more than 1 mg/kg and a total content of benz [a] anthracene, chrysene, benzo [b] fluoranthene, benzo [j] fluoranthene, benzo [k] fluoranthene, benzo [c] pyrene, benzo [a] pyrene and dibenz [a, h] anthracene of not more than 10 mg/kg; and B) one or more base oils each having a viscosity of not more than 4.0 mm | 2010-01-21 |
20100016191 | Copolymers Made With Allyl-Terminated Polyolefins And Unsaturated Acidic Reagents, Dispersants Using Same, and Methods of Making Same - Copolymers made with allyl-terminated polyolefins and unsaturated acidic reactants, dispersants using same, and methods of making same are provided. Under one aspect, a copolymer of an unsaturated acidic reactant and high molecular weight polyolefin, wherein the polyolefin comprises an allyl-terminated polymeric product, is provided. The allyl-terminated polymeric product is formed, e.g., by forming a quasi-living tert-halide terminated polyolefin under suitable quasi-living conditions, and contacting the tert-halide terminated polyolefin with an allylsilane compound and a Lewis acid. In some embodiments, the allylsilane compound includes allyltrimethylsilane. | 2010-01-21 |
20100016192 | Mannich Post-Treatment of PIBSA Dispersants for Improved Dispersion of EGR Soot - A composition of the reaction product of (a) an polyisobutylene substituted succinimide dispersant; (b) an amine component comprising at least one aromatic amine containing at least one N—H group capable of condensing with said carboxylic acid functionality; and (c) an aldehyde; which may optionally be reacted with (d) a maleinated copolymer, is a useful dispersant viscosity modifier. | 2010-01-21 |
20100016193 | Method for stabilizing diesel engine lubricating oil against degradation by biodiesel fuel - The lubricating oil used to lubricate diesel engines is stabilized against the detrimental degradation effects of biodiesel fuel by the addition to the lubricating oil of an additive concentrate comprising a premix of a first antioxidant, a second antioxidant of a type different from the first and an organometallic compound. | 2010-01-21 |
20100016194 | GREASE COMPOSITION FOR CONSTANT VELOCITY JOINT - A grease composition for a constant velocity joint is provided, which comprises a mineral oil as a base oil along with an alicyclic-aliphatic diurea thickener, a sulfur-ester-based additive, molybdenum dithiocarbamate (Mo-DTC), molybdenum dithiophosphate (Mo-DTP) and zinc dithiophosphate (Zn-DTP) as additives. The composition improves NVH performance by lowering a generated axial force and P.R. (plunging resistance) while increasing abrasion resistance. | 2010-01-21 |
20100016195 | Lube Base Oil, Lubricating Oil Composition For Internal Combustion Engine, And Lubricating Oil Composition For Drive Transmissoin Device - The lubricating base oil of the invention satisfies at least one of conditions (a) or (b) below. The lubricating oil composition for an internal combustion engine according to the invention comprises the lubricating base oil of the invention, an ashless antioxidant containing essentially no sulfur as a constituent element, and at least one compound selected from among ashless antioxidants containing sulfur as a constituent element and organic molybdenum compounds. Also, a lubricating oil composition for a power train device according to the invention comprises the lubricating base oil of the invention, a poly(meth)acrylate-based viscosity index improver and a phosphorus-containing compound. | 2010-01-21 |
20100016196 | PHOSPHITE STABILIZER FOR LUBRICATING BASE STOCKS AND THERMOPLASTIC POLYMERS - A substituted phosphite suitable for lubricating base stocks and thermoplastic polymers represented by the structure: | 2010-01-21 |
20100016197 | Cyclohexenyl Butenones and Fragrance Compositions Comprising Them - The present invention relates to substituted cyclohexenyl butenones of the formula | 2010-01-21 |
20100016198 | Compositions Comprising Sulfonated Estolides And Alkyl Ester Sulfonates, Methods Of Making Them, And Compositions And Processes Employing Them - Compositions comprising sulfo-estolides and alkyl ester sulfonates are described. Detergent formulations, such as laundry detergents, softeners, and other materials, containing any of these materials are disclosed, as well as personal care formulations, hard surface cleaner formulations, and automatic dishwasher detergent formulations. Laundry methods employing these formulations are also disclosed. These formulations are useful as laundry detergents and can be biodegradable, heavy duty liquids, 2× or 3× and up to 6× concentrates, low foaming, and/or effective in a high efficiency washing machine. Methods for laundering fabrics with the compositions are also disclosed. | 2010-01-21 |
20100016199 | DETERGENT COMPOSITION - A detergent composition contains a polyglycerol monoalkyl ether, water, a fat or oil, and a polyol. The polyglycerol monoalkyl ether is present in the composition at a content of 1 to 50 percent by weight based on the total amount of the composition. The detergent composition is useable as a foamable cleansing agent kind to the skin, exhibits superior detergency for oily cosmetics, and is usable even under wet conditions. | 2010-01-21 |
20100016200 | Silica Composite Capsules Obtained By Blending Water-Soluble Silane Derivative, Composition Containg The Same, And Transparent Gel-Form Composition - The present invention provides new silica composite capsules that can be easily prepared, a composition containing the silica composite capsules, and a transparent gel-form composition excellent in appearance transparency and texture in use, and in particular, a transparent gel-form composition with improved cleansing properties when used as a cleanser. Micelle/silica composite capsules can easily be obtained, in an aqueous system, by mixing a material capable of forming micelles in water and a water-soluble silane derivative having a specific structure in aqueous solution. In addition, emulsion/silica composite capsules wherein the periphery of emulsion particles in the inner phase is coated with silica, can easily be obtained by mixing a surfactant, water, an oil, and a water-soluble silane derivative having a specific structure. Moreover, a transparent gel-form composition showing excellent appearance transparency, the texture in use and cleansing properties, can be obtained by blending a water-soluble silane derivative having a specific structure into the formulation that contains a surfactant, an oil and water, and capable of taking a surfactant association structure with aqueous continuous phase or both of aqueous continuous phase and oil continuous phase in the formulation. | 2010-01-21 |
20100016201 | Graffiti Cleaning Composition - The invention relates to a cleaning composition characterized in that it can be used to clean graffiti from, inter alia, flexible, elastic and solid surfaces and synthetic fabrics printed with a selection of colors, silk-screen printed, painted with oil, vinyl or latex paint, automotive paint, as well as surfaces decorated with artistic patinas, metal surfaces with electrostatic paint, baked-on paint. One main advantage of the cleaning composition is that it cleans graffiti without removing paint from the printed matter or damaging the original underlying paint. | 2010-01-21 |
20100016202 | MATERIALS AND SYSTEMS FOR ADVANCED SUBSTRATE CLEANING - The embodiments of the present invention provide improved materials, apparatus, and methods for cleaning wafer surfaces, especially surfaces of patterned wafers (or substrates). The cleaning materials, apparatus, and methods discussed have advantages in cleaning patterned substrates with fine features without substantially damaging the features. The cleaning material includes polymers of one or more polymeric compounds. The cleaning materials can be used in a wide range of viscosity and pH to clean different types of surfaces. The cleaning materials are in liquid phase, and deform around device features to capture the contaminants on the substrate. The polymers entrap the contaminants preventing their return to the substrate surface. The cleaning apparatus is designed to dispense and rinse cleaning materials with a range of viscosities. | 2010-01-21 |
20100016203 | CLEANING AGENTS - The invention relates to machine diswahing agents containing specific polycarbonate-, polyurethane-, and/or polyurea-polyorganosiloxane compounds or precursor compounds thereof of the reactive cyclic carbonate and urea type which help to avoid the formation of water spots and filming after the use of the agents and accelerate the drying of dishes. | 2010-01-21 |
20100016204 | Cleaning agent - A cleaning agent made of a mixture of a first solution and a second solution wherein the first solution is a mixture of water and sodium bicarbonate which has been passed through a positively charged magnetic field and wherein the second solution is a mixture of water and sodium silicate which has been passed through a negatively charged magnetic field. | 2010-01-21 |
20100016205 | USE OF IONIC LIQUIDS AS AN ADDITIVE FOR CLEANING PROCESSES IN LIQUEFIED AND/OR SUPERCRITICAL GAS - The invention relates to the use of at least one ionic liquid or of a mixture of ionic liquids as a detergent for the cleaning of articles with a compressed gas. | 2010-01-21 |
20100016206 | DETERGENT HAVING AN ACTIVE INGREDIENT THAT IMPROVES THE PRIMARY DETERGENCY - The invention provides improvements in the primary detergency of detergents for washing textiles, particularly against oily stains and/or stains containing fat. These improvements are realized through the use of certain polycarbonate-, polyurethane-, and/or polyurea-polyorganosiloxane compounds or precursor compounds usable in the production thereof having certain reactive groups. | 2010-01-21 |
20100016207 | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid - The present invention provides methods of increasing the level or release of gamma aminobutyric acid (GABA) in the brain, treating Alzheimer's disease, Huntington's disease, symptoms thereof, anxiety, aggression, insomnia, cognitive or memory disturbances; seizures of any cause (e.g. idiopathic epilepsy), primary or metastatic brain tumors, depression (e.g. bipolar depression), or pain (e.g. neuropathic pain), comprising administration of glutamine, a salt thereof, or a glutamine-rich peptide. The present invention also provides methods for decreasing the level or release of GABA in the brain and treating hepatic encephalopathy, depressed consciousness, and coma, comprising decreasing dietary intake of glutamine. | 2010-01-21 |
20100016208 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS - Photoactivatable antimicrobial compounds and methods for the use thereof in the treatment of infections are provided. | 2010-01-21 |
20100016209 | Methods of Reducing Side Effects in Cancer Therapy - The present invention provides a method of decreasing side effects in a human or animal cancer patient due to radiation therapy or chemotherapy. With this method, methionine enkephalin is administered to the patient at least one time per week for a first time period, where the first time period is at least three weeks. In one embodiment, the first time period is one or two months. Methionine enkephalin is then administered to the patient one time per month for a second time period, where the second time period is at least one month, and where the second time period is consecutive to the first time period. In one embodiment, the total term of methionine enkephalin treatment is at least six months. Methionine enkephalin may be administered to the patient at the same time as, before, or after administration of radiation or chemotherapy. | 2010-01-21 |
20100016210 | Sensotherapy - The invention involves a preparation for the weight loss by means of appetite suppression and a method for administering the preparation to humans and other mammals. | 2010-01-21 |
20100016211 | Treatment of Melanoma With Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 2010-01-21 |
20100016212 | METHODS FOR TREATING PULMONARY HYPERTENSION AND COMPOSITIONS COMPRISING VASOACTIVE INTESTINAL PEPTIDE - A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity. or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can he delivered. A method for the treatment of cardiac arrest or pulmonary hypenension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention. | 2010-01-21 |
20100016213 | USE OF A DITERPENOID COMPOUND FOR TREATING DIABETES - A method for lowering the plasma glucose level in a subject and for treating diabetes with a diterpenoid compound. | 2010-01-21 |
20100016214 | CARBOHYDRATES MIXTURE - A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed,
| 2010-01-21 |
20100016215 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R) | 2010-01-21 |
20100016216 | Adiponectin and uses thereof - The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents. | 2010-01-21 |
20100016217 | DERIVATISATION OF GRANULOCYTE COLONY-STIMULATING FACTOR - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2010-01-21 |
20100016218 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s). | 2010-01-21 |
20100016219 | Ophthalmic compositions containing solubilized cyclosporin - An ophthalmic composition containing solubilized cyclosporin is able to be obtained in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms and at least one polysorbate surface active agent in an ophthalmically acceptable medium. The composition is stable without crystallization and/or precipitation of cyclosporin. The composition is suitable for treatment of ophthalmic disorders including keratoconjectivis Sicca and ocular rosacea. | 2010-01-21 |
20100016220 | GENES AND POLYPEPTIDES RELATING TO HUMAN COLON CANCERS - The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease. | 2010-01-21 |
20100016221 | METHOD OF DEGRADING PROTEIN BY CHAPERONE-MEDIATED AUTOPHAGY - The present invention provides a method of degrading a target protein in a subject comprising administrating to the subject an effective amount of any of: (a) a peptide comprising an HSC70-binding moiety and a target protein-binding moiety; and/or (b) a polynucleotide encoding the peptide of (a). | 2010-01-21 |
20100016222 | NOVEL AGENT FOR INDUCING APOPTOSIS COMPRISING MSX1 OR A GENE ENCODING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells. The Msx1 or homeodomain thereof can be effectively used for the treatment of tumors, in which wild-type p53 protein has lost its function by some mechanism that inactivates p53 proteins. | 2010-01-21 |
20100016223 | TREATMENT OF CARTILAGE DISORDERS WITH FGF-18 - This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle. | 2010-01-21 |
20100016224 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE - The present invention relates to a method of enhancing a pro-inflammatory immune response through the administration of the DEAD-box protein DDX3, as encoded by SEQ ID NO:1. The invention further extends to a method of suppressing an aberrant immune response, such at that associated with autoimmune conditions, through inhibition of DDX3. The invention also extends to a method of suppressing a pro-inflammatory immune response through the administration of the vaccinia virus protein K7. The invention further extends to the provision of an attenuated poxvirus wherein the K7R gene which encodes for the K7 protein is deleted or rendered non-functional. Pharmaceutical compositions comprising DDX3 inhibitory compounds, such as K7, are also provided. | 2010-01-21 |
20100016225 | CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY - Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer. | 2010-01-21 |
20100016226 | UNACYLATED GHRELIN AND ANALOGS AS THERAPEUTIC AGENTS FOR VASCULAR REMODELING IN DIABETIC PATIENTS AND TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1; and to pharmaceutical compositions comprising unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1. | 2010-01-21 |
20100016227 | LIGAND/LYTIC PEPTIDE COMPOSITIONS AND METHODS OF USE - Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components—the ligand and the lytic peptide—may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of “normal” host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells. | 2010-01-21 |
20100016228 | TRUNCATED BARD1 PROTEIN, AND ITS DIAGNOSTIC AND THERAPEUTIC USES - The invention concerns a novel polypeptide derived from the cleavage of the BARD1 protein, a nucleic acid encoding for said polypeptide, and their diagnostic and therapeutic uses, in particular for treating tumors. | 2010-01-21 |
20100016229 | Oral GLP-1 Formulations - The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent. | 2010-01-21 |
20100016230 | Treatment Of Inflammatory Bowel Diseases With Mammal Beta Defensins - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 2010-01-21 |
20100016231 | Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins - The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins. | 2010-01-21 |
20100016232 | Treatment Of Inflammatory Diseases With Mammal Beta Defensins - The present invention relates to suppression of TNF-alpha activity with mammal beta defensins, which has utility in the treatment of pathological conditions associated with tumor necrosis factor alpha. | 2010-01-21 |
20100016233 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 2010-01-21 |
20100016234 | SIGNAL PEPTIDES, NUCLEIC ACID MOLECULES AND METHODS FOR TREATMENT OF CARIES - Compounds that competitively inhibit binding of CSP to | 2010-01-21 |
20100016235 | Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof - The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer. | 2010-01-21 |
20100016236 | Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same - Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis. | 2010-01-21 |
20100016237 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2010-01-21 |
20100016238 | Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2010-01-21 |
20100016239 | HEPARIN BINDING MOTIF AND USE THEREOF - A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB, BXBBXB, XBBBXXBBBXXBBX, or TXXBXXTBXXXTBB, wherein X represents any amino acid, Z represents an aromatic amino acid, and B represents a basic amino acid and T represents a turn. | 2010-01-21 |
20100016240 | FACILITATING CELLS AND DIABETES AND METHODS RELATED THERETO - This disclosure describes methods of screening for compounds that increase the number of p-preDCs and/or Tregs. | 2010-01-21 |
20100016241 | METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization. | 2010-01-21 |
20100016242 | MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE - Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use. | 2010-01-21 |
20100016243 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid. | 2010-01-21 |
20100016244 | D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF - The invention relates to a D-glucopyranose 1-[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxybenzoate compound defined by formula (I). It applies in particular to the preparation and the use of this compound and of its derivatives for the preparation of medicaments for the treatment and/or prevention of infections with enveloped viruses, and in particular, in humans, the herpes virus, the Aids virus, the flu virus, the hepatitis B virus, the hepatitis C virus, the dengue virus and the ebola virus, and, in animals, the porcine pseudorabies virus, for example. | 2010-01-21 |
20100016245 | RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF - The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention. | 2010-01-21 |
20100016246 | FOOD COMPOSITION FOR FUNCTIONAL FOODS AND NUTRITIONAL SUPPLEMENTS - A food composition for functional foods and nutritional supplements is for preventing, reducing or treating cardiovascular diseases or mild manifestations thereof, obtained from the combination of extracts derived from citrus species, which contain between 25 and 80% by weight of hesperidin; between and 10% by weight of isonaringin; between 0.5 and 1% by weight of eriocitrin; and between 0.1 and 1% by weight of diosmin and the use of the composition in functional foods and nutritional supplements. | 2010-01-21 |
20100016247 | USING BUDDING YEAST TO SCREEN FOR INHIBITORS OF AURORA KINASES - Methods of screening for novel Aurora kinase inhibitors in higher organisms are provided using hypomorphic ipl1 mutant yeast cells. Putative Aurora kinase inhibitors identified by present screening methods may be useful in treating individuals having a proliferative disease, such as cancer. Chemical compounds identified by present methods as selectively inhibiting growth of hypomorphic ipl1 mutant yeast cells may be used in compositions. Compositions or compounds identified by such screening methods may be administered to an individual in need thereof. | 2010-01-21 |
20100016248 | TABLET FORMULATION - The invention relates to a tablet formulated for administration to an animal to treat parasite infestation. The tablet includes at least one macrocyclic lactone compound with anthelmintic activity dissolved in at least one organic solvent and subsequently formulated into a tablet. The tablets produced have a high degree of stability when stored over time and also provide the animal with a dose of agent sufficient to be therapeutically effective. | 2010-01-21 |
20100016249 | CANCER SENSITIZER COMPRISING GLUCOSAMINE, GLUCOSAMINE DERIVATIVES OR SALTS THEREOF - Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy. | 2010-01-21 |
20100016250 | TOLL-LIKE RECEPTOR 9 AGONISTS - The present invention provides TLR9 agonists comprising, as an active ingredient, a compound represented by formula (I): | 2010-01-21 |
20100016251 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2010-01-21 |
20100016252 | Mannich Base N-Oxide Drugs - Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments. | 2010-01-21 |
20100016253 | METHODS AND COMPOSITIONS RELATED TO HEIGHTENED APOBEC-1 RELATED PROTEIN (ARP) EXPRESSION - Disclosed are methods and compositions related to determining the status and mechanisms underlying long-term nonprogression of viral infections. | 2010-01-21 |
20100016254 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections. | 2010-01-21 |
20100016255 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B | 2010-01-21 |
20100016256 | Taxane Compounds for Treating Eye Disease - The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration. | 2010-01-21 |
20100016257 | METHOD OF TREATMENT FOR OSTEOARTHRITIS BY LOCAL INTRA-ARTICULAR INJECTION OF MICROPARTICLES - A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint. | 2010-01-21 |
20100016258 | PHOSPHONATE DERIVATIVES AS AUTOTAXIN INHIBITORS - The present invention provides β-hydroxy phosphonate compounds that are autotaxin inhibitors. | 2010-01-21 |
20100016259 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators - The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase. | 2010-01-21 |
20100016260 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) - The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors. | 2010-01-21 |
20100016261 | CHEMICAL COMPOUNDS - A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal. | 2010-01-21 |
20100016262 | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter alia to methods of inhibiting or reducing the likelihood of liver injury secondary to hepatitis, cirrhosis and a number of other disease states and conditions and further may be used to reduce the likelihood of a patient at risk or treating a patient for inter alia hepatitis, cirrhosis, non-alcoholic fatty liver diseases (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis and other disease states and conditions as otherwise described. Pharmaceutical compositions are also described. | 2010-01-21 |
20100016263 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL - A main object of the invention is to provide a novel useful vitamin D | 2010-01-21 |
20100016264 | TREATMENT FOR DRY EYE USING TESTOSTERONE AND PROGESTAGEN - The present invention comprises a composition and methods for treating eye conditions using a composition having a therapeutically effective amount of a progestagen, or a therapeutically effective amount of a progestagen with a testosterone; and pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface. | 2010-01-21 |
20100016265 | Anti-inflammatory composition and method for preparation - A pharmaceutical anti-inflammatory preparation and method for preparation and treatment of arthritis and related inflammatory conditions used for mild to severe pain for relatively long acting results. This anti-inflammatory preparation comprises anti-inflammatory corticord steroid in aqueous-like suspension, a muscle relaxant in oil-like composition, and amide anesthetic compound in aqueous-like composition and Vitamin B-12 in aqueous-like composition. It is prepared by mixing the anti-inflammatory preparation at a rate and for a time sufficient to create a suspended emulsion. The anti-inflammatory preparation is administered while in suspended emulsion by intramuscular patient injection. | 2010-01-21 |
20100016266 | Pyridine Imidazoles and Aza-indoles as Progesterone Receptor Modulators - The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist. | 2010-01-21 |
20100016267 | Pharmaceutical compositions for administraton to a sinus - Pharmaceutical compositions for delivering a drug to a sinus in a subject are provided. The compositions are formed by the combination of a carrier material and a drug and are specially adapted for delivery to a sinus. The compositions have no fixed shape, and the carrier material serves to increase the viscosity or specific volume of the composition after introduction of the composition into the sinus. Also provided are methods for delivering a drug to a subject. The methods entail administering a pharmaceutical composition according to the present invention directly to a sinus. The drug is then released from the composition to the sinus. The pharmaceutical compositions can be administered to a sinus in liquid form, for example, as a suspension or solution using standard techniques. Also provided is the use of a carrier material in the manufacture of a drug delivery composition. The drug delivery composition is for delivering a drug to a sinus in a subject. The composition comprises the carrier material combined with the drug to be delivered, and has no fixed shape. After the composition is introduced into a sinus, the carrier material serves to increase the viscosity or specific volume of the composition. | 2010-01-21 |
20100016268 | METHOD AND SYSTEM FOR DERMAL TISSUE TREATMENT - A method and article of manufacture of treating abnormal biological tissue. The article includes use of electrochemically treated water in combination with a biologically active tissue treatment component, particularly for dermal tissue treatment. The electrochemical treatment method includes exposure of untreated water to halogen containing species, such as hypochlorous and hypobromous acid. The biologically active tissue treatment component can be a cortisone or clobetasol containing media. | 2010-01-21 |
20100016269 | COMPOSITION OF PLANT STEROL AND PHOSPHATIDYLCHOLINE AND METHOD FOR PRODUCING THE SAME - The present invention is intended to discover a composition that contains a large amount of a plant sterol completely insoluble in water and exhibiting poor solubility in oil because of its extremely high crystallinity. Such composition can be easily dispersed in water, and to produce the composition. It has been discovered that a composition obtained by adding and dissolving a small amount of phosphatidylcholine in a plant sterol that is hardly soluble in water or in oil results in such composition easily dispersible in water. | 2010-01-21 |
20100016270 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to improve cardiac and/or cardiovascular health. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control cholesterol levels. | 2010-01-21 |
20100016271 | ANTI-DANDRUFF HAIR CONDITIONING COMPOSITIONS - A hair conditioning composition comprising a cationic surfactant, triglyceride oil, and an anti dandruff agent. | 2010-01-21 |
20100016272 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to heteroarylacrylamides of the formula I, | 2010-01-21 |
20100016273 | Use of Ezetimibe in the Prevention and Treatment of Cholesterol Gallstones - This invention discloses the use of compounds of the azetidinone family in the prevention or treatment of cholesterol gallstone disease of the biliary tree in mammals. This invention is in the general area of cholesterol stones disease in the biliary tree and gallbladder. In particular, the invention evidences that the use of drugs that specifically block cholesterol intestinal absorption inhibit the onset of cholesterol stone disease in the biliary tree. These drugs act by decreasing biliary cholesterol secretion, and at the same time increasing the biliary flow and the hepatic secretion of endogenous compounds (e.g. bile salts, phospholipids) into the bile, hi turn, these endogenous compounds contribute to inhibiting cholesterol precipitation and the formation of gallstones in the biliary tree. | 2010-01-21 |
20100016274 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS - Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity. | 2010-01-21 |
20100016275 | NOVEL COMPOUND 395 - A compound of formula (1) | 2010-01-21 |
20100016276 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF A CARBAPENEMASE GENE - Compositions and methods for the rapid and sensitive detection of a carbapenemase in a sample is provided. The compositions include novel primer and probe compositions for use in detecting the presence of this enzyme in a sample, particularly using PCR methods. These primers and probe sets can be used in amplification methods (such as PCR, particularly quantitative PCR) and packaged into kits for use in amplification methods for the purpose of detecting carbapenemase in a test sample, particularly a patient sample, particularly a direct sample. Thus, in one embodiment, the present invention provides for novel oligonucleotide primers set forth in SEQ ID NOs:1, 2, 4, 5, 7, 8, 14, 15, 17, 18, and 20, and the novel oligonucleotide probe sequences set forth in SEQ ID NOs:3, 6, 9, 16, and 19. These sequences can be used in a method of detecting carbapenemase in a sample. | 2010-01-21 |
20100016277 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS - Compounds of formula I | 2010-01-21 |
20100016278 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to heteroarylcyclopropanecarboxamides of the formula I, | 2010-01-21 |
20100016279 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 - The invention concerns bicyclic compounds of Formula I | 2010-01-21 |
20100016280 | Low Dosage Serotonin 5-HT2A Receptor Agonist To Suppress Inflammation - Activation of 5-HT | 2010-01-21 |
20100016281 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS - Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases. | 2010-01-21 |
20100016282 | NOVEL HETEROCYCLYL COMPOUNDS - The invention is concerned with novel heterocyclyl compounds of formula (I) | 2010-01-21 |
20100016283 | COMPOUNDS AND USES THEREOF - 150 - Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders. | 2010-01-21 |
20100016284 | COMPOUNDS AND USES THEREOF - 151 - This invention relates to novel compounds having the structural Formula I below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders. | 2010-01-21 |
20100016285 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE - The blow-described formula (I)
| 2010-01-21 |